LFMD — LifeMD, Inc.

LifeMD (LFMD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $46.9 million, up 4% year-over-year.
• Full Year Revenue: $194.1 million, a 25% increase from 2024.
• Active Subscribers: 322,000 at quarter-end, a 16% year-over-year increase.
• Gross Margin: 87.1% for Q4, up 570 basis points year-over-year.
• GAAP Net Income: $19 million ($0.41 per share) for Q4, including a one-time gain from the sale of WorkSimpli. Excluding this, a net loss of $1.9 million ($0.04 per share) was reported.
• Adjusted EBITDA: $4.8 million for Q4, up from $1.1 million in the prior year.
• Cash Position: $36.8 million with no debt.

2. Strategic Updates and Business Highlights

• Patient Acquisition: Over 1,200 new patients onboarded daily, with weight management seeing record sign-ups of nearly 700 per day.
• Partnerships: Launched oral Wegovy in collaboration with Novo Nordisk, enhancing access to weight management therapies.
• Women's Health Initiative: Significant investment in women's health offerings, including the acquisition of Optimal Human Health and partnerships with recognized experts in the field.
• Pharmacy Operations: The affiliate pharmacy is now licensed in all 50 states, processing approximately 20,000 prescriptions monthly, with a focus on personalized compounded medications.
• AI Integration: Development of AI-driven clinical decision support tools aimed at enhancing patient care and operational efficiency.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $48 million and $49 million, with an adjusted EBITDA loss of $4 million to $5 million due to increased investment in patient acquisition.
• Full Year 2026 Revenue Guidance: Projected between $220 million and $230 million, with adjusted EBITDA expected to be between $12 million and $17 million.
• Long-Term Goals: Anticipate annualized revenue exceeding $250 million and adjusted EBITDA exceeding $25 million by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Net Losses: Despite revenue growth, the company reported a net loss from continuing operations, indicating ongoing challenges in achieving profitability.
• Conversion Rates: While initial demand for women's health offerings is strong, conversion rates have been a challenge, requiring further investment and optimization.
• Competitive Pressures: Increased competition in the weight management space, notably from major players like Amazon and Eli Lilly, poses risks to market share and pricing strategies.
• Insurance Integration: While expanding insurance coverage is a priority, the company is still in the early stages of proving the long-term value of insured patients compared to cash pay patients.

5. Notable Q&A Insights

• Wegovy Demand: Demand for the Wegovy pill has been strong since its launch, with significant new patient acquisition attributed to this product.
• Marketing Strategy: The company is leveraging new media partnerships and onboarding smaller employers to drive patient acquisition, while maintaining a similar marketing strategy to previous years.
• Insurance Impact: Early indications suggest that patients using insurance may have better retention and lifetime value, but further data is needed to confirm this.
• Women's Health Performance: Initial metrics show promising retention rates in women's health, with the potential for significant revenue contribution in the future, although it may not be EBITDA positive in its first year.

Overall, LifeMD demonstrated solid financial performance and strategic growth initiatives while facing challenges related to competition and conversion rates in new service offerings. The company remains optimistic about its growth trajectory and the potential of its diversified health services.